We reported recently that suppression of the renal 1 alpha ,25-dihyroxyvita
min D-3 (1 alpha ,25-(OH)(2)-D-3) production in aP2-agouti transgenic mice
by increasing dietary calcium decreases adiposity. However, it was not clea
r whether this modulation of adipocyte metabolism by dietary calcium is a d
irect effect of inhibition of 1 alpha ,25-(OH)(2)-D-3-induced [Ca2+]i. Acco
rdingly, we have now evaluated the direct role of 1 alpha ,25-(OH)(2)-D-3.
Human adipocytes exhibited a 1 alpha ,25-(OH)(2)-D-3 dose-responsive (1-50
nM) increase in [Ca2+]i (P<0.01). This action was mimicked by 1<alpha>,25-d
ihydroxyluministerol(3) (1 alpha ,25-(OH)(2)-lumisterol(3)) (P<0.001), a sp
ecific agonist for a putative membrane vitamin D receptor (mVDR), and compl
etely prevented by 1<beta>,25-dihydroxyvitamin D-3 (1 beta ,25-(OH)(2)-D-3)
, a specific antagonist for the mVDR. Similarly, 1 alpha ,25-(OH)(2)-D-3 (5
mM) caused 50%-100% increases in adipocyte fatty acid synthase (FAS) expre
ssion and activity (P<0.02), 61% increase in glycerol-3-phosphate dehydroge
nase (GPDH) activity (P<0.01), and an 80% inhibition of isoproterenol-stimu
lated lipolysis (P<0.001), whereas 1<beta>,25-(OH)(2)-D-3 completely blocke
d all these effects. Notably, 1 alpha ,25-OH)(2)-lumisterol(3) exerted more
potent effects in modulating adipocyte lipid metabolism, with 2.5- to 3.0-
fold increases in FAS expression and activity (P<0.001) and a threefold inc
rease in GPDH activity (P<0.001). Also 1 alpha ,25-(OH)(2)-lumisterol3 was
approximately twice as potent in inhibiting basal lipolysis (P<0.025), wher
eas 1<beta>,25-(OH)(2)-D-3 completely blocked all these effects. These data
suggest that 1 alpha ,25-(OH)(2)-D-3 modulates adipocyte Ca2+ signaling an
d, consequently, exerts a coordinated control over lipogenesis and lipolysi
s. Thus, a direct inhibition of 1 alpha ,25-(OH)(2)-D-3-induced [Ca2+](i) m
ay contribute to an anti-obesity effect of dietary calcium, and the mVDR ma
y represent an important target for obesity.